Home › Markets › Health Care › OVID

Ovid Therapeutics Inc. (OVID)

OVID trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$2.19
-9.13% on the day
Market cap
$427.7M
Small cap
Revenue · 2025
$7.3M
+1181.3% on 2024
Net income · 2025
-$17.4M
-239.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerOVID on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001636651
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$7.3M
Net income-$17.4M
Operating income-$42.4M
Net margin-239.9%
Operating margin-585.2%
Revenue growth+1181.3%
Cash$13.2M
Total assets$150.9M
P/E (computed)Net income was not positive
P/S (computed)59.0×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-27
Latest annual report10-K2026-03-18
Latest quarterly / interim10-Q2026-08-13
Latest current report8-K2026-08-13
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 532 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.1%
1 month-19.9%
3 months-11.4%
Year to date+33.1%
1 year+37.3%
From 52-week high-26.7%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PRTAProthena Corporation plc$8.36-0.83%$429.2M
NGNENeurogene Inc. Common Stock$21.56-11.78%$431.4M
DMACDiaMedica Therapeutics Inc.$7.82-4.63%$421.7M
ASMBAssembly Biosciences Inc.$20.34-10.67%$414.1M
KMDAKamada Ltd.$7.69-1.91%$443.8M
RZLTRezolute Inc. Common Stock (NV)$4.61-5.34%$445.9M
ARVNArvinas Inc.$6.84-8.19%$447.2M
SPRYARS Pharmaceuticals Inc.$4.05-3.11%$402.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier